Form 4 for XENE Xenon Pharmaceuticals Inc.
Accepted 2026-05-13 21:40:43 ET · period of report 2026-05-12 · accession 0001193125-26-222369 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2026-05-13 21:40 | 2026-05-12 | XENE | GANNON STEVEN | Dir | M - OptEx | $7.38 | +3,500 | 10.6K | +49% | +$25.8K |
| D | 2026-05-13 21:40 | 2026-05-12 | XENE | GANNON STEVEN | Dir | M - OptEx | $0.00 | -3,500 | 0 | -100% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Shares | 2026-05-12 | M | A | 3,500 | $7.38 | 10,641 | D | — | — | |
| 2 | Derivative | Stock Option (Right to Buy) | 2026-05-12 | M | D | 3,500 | $0.00 | 0 | D | $7.38 · — to 2026-06-01 | 3,500 Common Shares | (F1) The shares subject to the option are fully vested and exercisable. |